Co-investors in this round include 9UnicornsVenture Catalyst and Nihar Parikh, Founder of 4point0 Health Ventures and Sriram Natarajan, Founder of Molbio.
The funds will be used to increase the reach of diabyflyDigital clinical and clinically proven programs to prevent, manage and reverse diabetes.
It will also be used to enhance Fitterfly’s technology stack to deliver unparalleled clinical insights.
Fitterfly has so far managed over 20,000 patients through a 360-degree care approach and medically prescribed therapy by over 200 doctors across India.
The company says this has resulted in an average reduction of 1.5% in HbA1c, which is comparable to the reduction seen in oral diabetes drugs. While a large number of people in the early stages of the disease have been able to get completely reversal, those in the later stages were able to reduce their dependence on drugs, achieve better sugar control, and avoid complications.
Find stories that interest you
“We want to take our clinically proven diabetes and weight management system to the people who need it most,” said Arbinder Singhal, Chief Executive Officer (CEO) and Co-Founder, Fitterfly.
Singal said, “This funding will allow us to strengthen our research, launch new verticals in the heart health sector and grow our customer base by reaching out to people living with diabetes as well as doctors and organizations in the area of ​​chronic disease management. will help.” Told.
The Single Fund will help millions of patients prevent, reverse and manage chronic conditions such as diabetes, obesity and heart disease.
Established in 2016 by Singal and Shailesh Gupta, Fitterfly has over 200 employees and is headquartered in Navi Mumbai. The company has raised a total of $16.6 million so far.